Attending the Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, this year are not only researchers and physicians, but also a number of different blog writers. The below is some of what these writers have been hearing and writing about.
2016 Liver Meeting Highlights being Written about by Two Attending Blog Writers
Summary: A general description of the Liver Meeting 2016. “There were quite a few presentations on fatty liver diseases (FLD) such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). FLDs are rapidly overtaking hepatitis C as the most prevalent liver threat.”
Summary: A post about two of Porter’s favorite conference posters, Abstract #868 Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium, by Michael W. Fried, et al., and Abstract #911 Alcohol Use and Hepatitis C Virus Treatment Outcomes Among 15,151 Patients Receiving Direct Antiviral Agents, by Judith Tsui, et al. Editorial comments included.
Summary: A post highlighting Abstract # LB-15 Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration(SURVEYOR-II, Part 4), by Tarek Hassanein, et al., and Abstract #831 Hepatitis C (HCV) Virologic Outcomes in Veterans Taking Ledipasvir/Sofosbuvir With Concomitant Acid Suppressing Medication – Austin Chan, et al. Editorial comments included.
- AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients
Summary: The hep C treatment Zepatier (grazoprevir/elbasvir) and Sovaldi (sofosbuvir) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hep C genotype 3 and liver cirrhosis, matching rates seen in easier-to-treat patient groups.
- AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Stellar Clinical Trial Results
Summary: Direct-acting antiviral treatments have real-world rates similarly found in clinical trials, without major differences between treatment regimens.
Summary: Being cured of hepatitis C with direct-acting antiviral treatment doesn’t increase one’s risk of developing hepatocellular carcinoma (HCC) and may reduce it. (Canadian Study)
More information about the Liver Meeting or information about these and other studies can be found in our blog post The Liver Meeting 2016 Hep C Abstract Highlights (Part1), on the American Association for the Study of Liver Diseases (AASLD)’s website, or by clicking the links listed above.